The main feedback loop driving circadian rhythm in mice is controlled in part by the genes encoding the cryptochromes Cry1 and Cry2. Targeted mutation of both Cry1 and Cry2 delay the early onset of tumor formation in p53 null mutant mice. 
Introduction
Cryptochrome (Cry) is the main repressor in the transcription-translation feedback loop that generates circadian rhythmicity in mice (1) . Recently we reported that Cry mutation in Ras-transformed p53 null mouse skin fibroblasts sensitized the cells to apoptosis by UV and UV-mimetic agents such as oxaliplatin (2, 3) . Further analysis revealed that this enhanced apoptosis was caused by the amplified upregulation of the p73 tumor suppressor due to the high level of the clock controlled transcription factor Egr1 in Cry null cells (3) .
Since p73 is a DNA damage inducible gene (4, 5) we wished to find out the effect of other DNA damaging agents on p73 induction and apoptosis in cells with and without a functional circadian clock. The p73 gene has a complex regulatory mechanism that includes E2F1, Egr1, and C-EBPα transcription factors. There are 1 C-EBPα, 3 E2F1, and 5 Egr1 binding sites in the p73 promoter (4) (5) (6) (7) (8) . The p73 protein level is mainly regulated by transcription that is activated by E2F1 and Egr1 and is repressed by C-EBPα. DNA damage by doxorubicin or cisplatin causes dissociation of C-EBPα from the promoter and its nuclear export enabling the transactivators to upregulate p73 transcription (4) . Interestingly, of these two transcriptional activators Egr1 is a circadian clock controlled gene with a robust rhythmicity (9) whereas E2F1 is not controlled by the circadian clock (10) . While investigating the effect of circadian clock disruption on cellular response to DNA damage we discovered that circadian clock disruption by Cry mutation led to elevated level of expression of Egr1 which resulted in high level of expression of p73 upon DNA damage by UV or oxaliplatin and enhanced apoptosis resulting in increased clonogenic cell death by these genotoxicants (3) .
Here, we wished to investigate other DNA damaging agents that generate DNA lesions that encompass the entire spectrum of repair pathways for their effects on p73-medaited apoptosis in the absence or presence of Cry in p53 null cells in order to find out whether Cry mutation sensitizes these cells to all genotoxicants. We used UV and oxaliplatin (UV-mimetic) whose major lesions are repaired by nucleotide excision repair, ethylmethane sulfonate (EMS) that induces base alkylation repaired by base excision repair, doxorubicin that induces double-strand breaks repaired by non-homologous end-joining and homologous recombination, mitomycin C that induces interstrand crosslinks repaired by recombination and translesion synthesis, and camptothecin that induces DNA-protein crosslinks repaired by proteolysis and recombination (11, 12) . We found that at equitoxic doses only the UV- Author Manuscript Published OnlineFirst on November 13, 2012; DOI: 10.1158/0008-5472. CAN-12-1994 mimetic (UV and oxaliplatin) and the radiomimetic (doxorubin and camptothecin) agents induced p73 expression. Furthermore, surprisingly, we found that while oxaliplatin induces p73 through Egr1-mediated transcriptional upregulation, doxorubicin induces p73 through E2F1-mediated transcriptional upregulation. As a consequence the clonogenic killing and apoptotic effects of oxaliplatin are enhanced by Cry mutation that causes constitutive upregulation of Egr1 but the cell killing and apoptotic effects of doxorubicin are not affected by Cry mutation. As oxaliplatin plus doxorubicin combination is used in various chemotherapeutic regimens (13) these findings may help in designing more effective drug delivery protocols for cancer therapy. supplemented with complete protease inhibitor cocktail (Roche), and 50 μg of lysate were loaded to pre-cast 4-12% gradient SDS/PAGE (Invitrogen).
Materials and Methods

Establishment
Immunoprecipitation. Cells were lysed in RIPA buffer supplemented with complete protease inhibitor cocktail (Roche). After pre-clearing with protein A/G agarose plus (Santa Cruz) for 1 hr at 4°C, whole-cell lysates were used for immunoprecipitation with the indicated antibody. one μg of the commercial antibody was added to 1 ml of the cell lysate and incubated at 4°C for 8-12 hrs. After adding protein A/G agarose beads, incubation was continued for an additional 1 hr. The immunoprecipitates were then washed extensively with RIPA buffer and eluted by boiling them with an SDS loading buffer for 5 min.
Statistical analysis.
Values are shown as mean ± SD of at least 3 experiments calculated using a two-tailed student t test. Author Manuscript Published OnlineFirst on November 13, 2012; DOI: 10.1158/0008-5472. CAN-12-1994 Cry mutation on these repair pathways. Fig. 1 shows the result of clonogenic assays for all these treatments. In agreement with our previous report, the killing by UV (Fig. 1A) and oxaliplatin (UV-mimetic agent, Fig. 1B ), which produce bulky DNA adducts that are repaired exclusively by nucleotide excision repair (11) , is enhanced by Cry mutation.
Results
Clonogenic killing by various genotoxicants of
Interestingly, the killing effect of none of the other DNA damaging agents is influenced by Cry ( Fig. 1C-F) . This suggests that Cry mutation specifically affects the lethality of UVmimetic agents that produce bulky DNA adducts. We have previously shown that Cry mutation enhanced the clonogenic cell death of p53 null cells by UV and oxaliplatin by amplifying the intrinsic apoptotic response to these agents through increased transcription of p73 tumor suppressor (3). Therefore, we decided to analyze the response of p53 -/-and p53
Cry1/2 -/-cells to these various DNA damaging agents in order to find out if the apoptosis enhancement by Cry mutation was restricted to apoptosis induced by UV-mimetic agents.
Effect of Cry mutation on apoptosis induced by full spectrum of genotoxicants. We performed apoptosis assays at equitoxic doses of all 6 genotoxicants used in the survival assay by employing doses that gave 50% survival in the clonogenic assay. We probed for apoptosis by measuring PARP and caspase 3 cleavage (14) Fig. 2A-D) ,
indicating that, dependent on the genotoxicant, different apoptosis kinetics or other modes of cell death are responsible for clonogenic killing. Second, and most importantly, within the examined time frame, apoptosis is enhanced by Cry mutation only in cells treated with UV and oxaliplatin, in agreement with the clonogenic survival data that show that Cry mutation enhances only the killing effects of these two agents (Fig. 1A, B) . Finally, even though under our experimental conditions, the doxorubicin-induced apoptosis is not amplified by Cry CAN-12-1994 mutation enhanced this response by upregulating p73 (3) we examined the effect of doxorubicin and UV/oxaliplatin along with those of other genotoxicants on p73 induction.
Mechanisms of p73 upregulation by radiomimetic and UV-mimetic agents. We treated cells with the 6 genotoxic agents used in the clonogenic survival assay and followed p73 induction for 12 hrs. The results are shown in Fig. 3A . In agreement with the apoptosis data, UV-mimetic treatments (UV and oxaliplatin)-caused p73 transcriptional upregulation in both
p53
-/-(3) and p53 +/+ (Fig S2) background is amplified by Cry mutation. In contrast, the extent of p73 induction by doxorubicin and camptothecin is comparable to that achieved by UV-mimetic treatments but is independent of the Cry status of the cell line (Fig. 3A, B) . Thus, it appears that while UV/oxaliplatin and doxorubicin/camptothecin induce p73 efficiently there is a difference between the induction mechanisms because one is affected by the status of Cry and the other is not.
To find out the cause of this differential effect of Cry on cellular response to the two types of DNA lesions (bulky adducts vs. double-strand breaks) known to induce p73 we examined the effects of these two types of DNA damaging agents on two transcription factors known to be involved in DNA damage-induced upregulation of p73, the E2F1 and Egr1 Importantly, however, doxorubicin upregulates E2F1 and causes its phosphorylation and acetylation. These are necessary for E2F1 activity but UV has no effect on E2F1 levels and posttranslational modification (15) (16) (17) (18) (Fig. 4A) . Of special relevance the effects of doxorubicin on E2F1 is independent of the Cry status of the p53 -/-cell lines, consistent with the clonogenic and apoptosis assays that the clock does not affect cellular response to doublestrand breaks as determined by these two endpoints.
We investigated the effects of E2F1 and Egr1 in more detail using doxorubicin (double-strand breaks) and oxaliplatin (bulky adducts) as models for clock effects on cellular response to the two types of DNA damage and also because these two drugs are component
Research. CAN-12-1994 of several frontline cancer therapy regimens. The findings in Fig. 4A provide a plausible explanation for the differential effects of Cry mutation on cellular response to damage by UV-mimetic and radiomimetic agents: The upregulation of p73 by E2F1 following DNA damage by radiomimetics is the predominant regulatory mechanism (15) (16) (17) (18) (Fig. 4E) . To recapitulate, double-strand breaks upregulate p73 through E2F1 and since E2F1 is not a clock-controlled gene, clock disruption through Cry mutation does not affect apoptosis induced by doxorubicin. In contrast, oxaliplatin upregulates p73 through Egr1 which has a clock-controlled promoter and therefore the high level overproduced Egr1
in Cry mutant cells strongly enhances oxaliplatin-induced apoptosis in p53 mutant cells.
Discussion
We recently reported that cryptochrome mutation rendered the p53 null and the Rastransformed p53 null cells, but not cells with wild-type p53, more susceptible to killing by agents that activate either the intrinsic or extrinsic apoptosis pathways (3, 19) . In those studies UV or oxaliplatin were used to initiate intrinsic apoptosis (3) and TNFα to initiate extrinsic apoptosis (19 CAN-12-1994 initiate extrinsic apoptosis (14) it is of interest to determine whether intrinsic and extrinsic apoptosis or other death forms induced by a variety of agents are similarly potentiated by Cry mutation. Here we have investigated the contribution of Cry to clonogenic cell death and to intrinsic apoptosis induced by a set of genotoxicants that generate DNA lesions that are repaired by each of the major DNA repair pathways including base excision repair, nucleotide excision repair, double-strand break repair, and crosslink repair. We find that apoptosis and clonogenic cell death by genotoxicants in p53 null background is enhanced by Cry mutation exclusively for UV-mimetics-induced DNA damage and no other. Further, we present evidence indicating that the enhanced apoptosis and clonogenic death by UV-mimetic agents in Cry mutant background is due to the upregulation of the clock-controlled transcription factor Egr1 in Cry mutant cells which lead to high level of induced expression of p73 tumor suppressor/apoptosis promoter.
In cells with functional p53, apoptosis by genotoxic agents is mainly controlled by this tumor suppressor (20) . Only in p53 mutant cells p73 becomes the arbitrator of cell fate by intrinsic apoptosis (21) . In contrast to p53, DNA damage-induced upregulation of p73 is mainly by transcriptional induction, although post-transcriptional modifications also make some contribution (4) (5) (6) (7) (8) . The transcriptional regulation of p73 has not been investigated in great detail. Current knowledge may be summarized as follows: The p73 promoter ( 2000 bp preceding transcriptional start site) contains, in the 5' to 3' direction, 5 Egr1, 1 C-EBPα, and 3 E2F1 binding sites (Fig. 5) . Egr1 and E2F1 are transcriptional activators while C-EBPα functions as a repressor. In most cell types in the absence of DNA damage the p73 expression is rather low (8) . However, all 3 transcription factors regulating p73 expression are subject to regulatory mechanisms themselves: Egr1 is controlled by the circadian clock (3, 9), C-EBPα is controlled by post-translational modification and nucleo-cytoplasmic shuttling and E2F1 is controlled by the cell cycle and by DNA damage-induced phosphorylation and acetylation which stabilize the protein and enhance its activity (15) (16) (17) (18) 22) . Upon DNA damage, C-EBPα is phosphorylated, released from the p73 promoter, and excluded from the nucleus; E2F1 is acetylated and stabilized, leading to 10-30 fold induction of p73 transcription from the promoter which is no longer repressed by C-EBPα. Of the two positive transcription factors E2F1 appears to have the predominant effect. However, the phosphorylation and acetylation CAN-12-1994 of E2F1 are induced by IR and radiomimetic agents such as doxorubicin but not by UV or UV-mimetic agents such platinum-based drugs. As a consequence it might be expected that in our experimental system doxorubicin-induced p73 upregulation which is predominantly controlled by E2F1 would not be affected by the presence or absence of a functional circadian clock because E2F1 is not controlled by the clock. In contrast, upregulation of p73 by UV and UV-mimetic agents seems to be mediated primarily by Egr1 because UV does not affect posttranslational modification of E2F1 and its activity (16) (17) (18) . Furthermore, since Egr1 is under robust clock control (3, 9), in Cry mutants in which the inhibitory arm of the transcription-translation feedback loop is non-functional Egr1 is highly elevated leading to significantly enhanced DNA damage-inducible p73 transcription even in the absence of contribution from E2F1. Because doxorubicin plus oxaliplatin combination is included in several chemotherapy regimens these findings should be taken into account for optimal efficacy with minimal side effects. 
Footnotes
